Intravenous Vitamin C is Selectively Toxic to Cancer Cells

National Institutes of Health scientists have confirmed the concepts that vitamin C is selectively toxic to cancer cells and that tumor-toxic levels of vitamin C can be attained using intravenous administration. The article, published in the September 12, 2005 issue of the *Proceedings of the National Academy of Sciences*, concluded, "These findings give plausibility to intravenous ascorbic acid in cancer treatment."

Orthomolecular medical researchers, including Nobel laureate Linus Pauling, have long recognized the great importance of vitamin C in fighting cancer. Scientists associated with the Bio-Communications Research Institute (BCRI) in Wichita, Kansas have published 20 scientific articles on the subject. BCRI researchers first reported in 1995 that vitamin C in sufficient amounts is selectively toxic to tumor cells. The authors concluded that tumor-toxic levels of vitamin C could be achieved only by giving the vitamin intravenously. Subsequent research from BCRI, published in the *British Journal of Cancer* in 2001, was the first to describe in detail the pharmacokinetics of high doses of intravenous vitamin C.

"It is gratifying to have our research on vitamin C and cancer confirmed by scientists at the prestigious National Institutes of Health," said Neil Riordan, PhD, BCRI's Research Director. "The findings reinforce our goal and commitment to pursue cutting edge cancer research," added Michael Gonzalez, PhD, DSc of the University of Puerto Rico.

BCRI's vitamin C research was headed by its founder, Hugh D. Riordan, MD. The research team includes Dr. Xiaolong Meng, Dr. Joseph Casciari, Dr. Nina Mikirova, Dr. Jie Zhong, Dr. James A. Jackson, Dr. Don Davis, Dr. Jorge Miranda, Dr. Michael Gonzalez, Dr. Neil Riordan, and Mr. Paul Taylor.

What is Orthomolecular Medicine?

Linus Pauling defined orthomolecular medicine as "the treatment of disease by the provision of the optimum molecular environment, especially the optimum concentrations of substances normally present in the human body." Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Take the Orthomolecular Quiz at http://www.orthomolecular.org/quiz/index.shtml The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

ANCIENT FORMULAS, INC.
Producer/Manufacturer of Health Formulations

HYPERTENSION • ALLERGIES • ARTHRITIS • DIABETES

For the past 15 years, Ancient Formulas, Inc. has been manufacturing a full line of unique herbal products based on ancient Persian text, specializing in doctor-tested and approved formulations addressing hypertension, allergies, diabetes, prostatitis, urinary tract infections, hyper-cholesterolemia, acne, arthritis, and joint inflammation, constipation, detoxification, thyroidism, weight loss, edema, sport injuries and support for menopause, besides private labeling and formulations.

We are pleased to announce that Ancient Formulas, Inc. has moved to a new, larger facility. Our new address is:

638 W. 33rd St. North • Wichita, Kansas 67204

For product information and orders please call: 800-543-3026

Editorial Review Board:
Abram Hoffer, MD
Harold D. Foster, PhD
Bradford Weekes, MD
Carolyn Dean, MD, ND
Eric Patterson, MD
Thomas Levy, MD, JD
OMNS Editor:
Andrew W. Saul, PhD
omns@orthomolecular.org
BCRI contact person:
Renee Olmstead
bcri@brightspot.org
To subscribe at no charge: http://orthomolecular.org/subscribe.html

References
3. Full text papers listed and accessible at no charge at http://www.orthomolecular.org/quiz/index.shtml